This is a headline on two lines that describes the page

Amplifier™ is developing ATX-304, a pan-AMPK activator, with the goal of treating cardiometabolic and aging-related diseases

ATX-304

(Formerly 0304)

Phase II

Indication:

Collaborator:

Therapeutic Area:

Cardiometabolic Diseases

Development
Stage:

Phase 2

Molecule:

Clinical trial news:

Amplifier is developing ATX-304 that promotes pan-AMPK activation as a first-in-class compound with unique properties

ATX-304 has been shown in cell-free systems and intact cells to activate AMPK and has shown beneficial metabolic and cardiovascular effects in pre-clinical models.

In early human trials with exposure up to 4 weeks, ATX-304 was found to be safe and well tolerated.

ATX-304 has multiple therapeutic applications in metabolic conditions and cardiovascular diseases.

Steneberg, P., et. al. JCI Insight. 2018. 3(12). e99114. DOI: 10.1172/jci.insight.99114.
Ericsson, M., et. al. Commun. Biol. 2021. 4(1306). DOI: 10.1038/s42003-021-02837-0.

Pipeline Q&A

Sit

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Laboriosam Labore

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Inventore Voluptas

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Omnis Quod Consequuntur Alias

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Sapiente

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

This is a headline on two lines that describes the page

Amplifier is developing ATX-304 that promotes pan-AMPK activation as a first-in-class compound with unique properties

Pipeline Q&A

Sit

Laboriosam Labore

Inventore Voluptas

Omnis Quod Consequuntur Alias

Sapiente

Something short and sweet, but memorable